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ABSTRACT 
The objective of the present study was to evaluate the efficacy of a dry extract of Passiflora 
incarnata L. (Sedanxio®) in patients consulting for anxiety in general practice. A total of 2928 
patients were included by 219 general practitioners. Patients were evaluated at baseline and 2 
weeks later using the Hamilton Anxiety Scale. Results showed a very significant improvement in 
anxiety scores, from 25.6 (SD = 8.3) at baseline visit to 15.4 (SD = 7.7) at follow up visit (-41%) 
(p < 0.0001). The Hamilton psychic and somatic subscores improved similarly. In addition, 
15.6% of the patients could be considered in remission at visit 2 (Hamilton Anxiety Scale less 
than 7). These results demonstrate the interest of Passiflora incarnata as a first line treatment of 
anxiety symptoms. 
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In Western countries, an increasing number of patients is suffering from anxiety disorders due 
to hectic modern life environment, professional and/or family stress, and also ageing. Up to a 
certain point, these problems can be handled by the patients themselves but, if they persist or 
deteriorate, they require medical advice and treatment. Besides recommendations for a 
alleviating daily stress, for a better life style, or even for psychological support, general 
practitioners (GP) will prescribe medications often to answer their patient’s demands and 
concerns (Ansseau, 2003).  
During the past decades, many patients have been treated right away with benzodiazepines 
(BZD), drugs known to have a high efficacy but which may also entail serious side effects, 
interactions or contra-indications (Ansseau, 1996). In particular, they can be responsible for 
drowsiness, memory difficulties, paradoxical reactions with acute aggressiveness or depressive 
symptoms. The most serious danger with benzodiazepines however is their potential for abuse 
and dependence. Therefore, the tendency today is to reduce the use of BZDs. Clearly a lot of 
patients suffering from tension, stress, insomnia or from mild to moderate anxiety do not need 
BZDs as a first intention treatment of their disorders. In this context, dry extract of Passiflora 
incarnata L. (Sedanxio®), a plant-based medication, is traditionally used to treat anxiety 
problems of mild to moderate severity or sleep disturbances. Several studies have suggested the 
efficacy of Passiflora in anxiety disorders (Miyasaka et al., 2007). In particular, Passiflora 
showed similar efficacy as compared to oxazepam but significantly less impairment of job 
performances (Akhondzadeh et al., 2001). The evaluation of activity parameters of passiflora 
dry extract capsules according to a “star” model showed moderate activity on psychic anxiety, 
weak effect on somatic anxiety, very weak sedative/hypnotic effect, and an absence of muscle-
relaxing and antiepileptic activity (Ansseau, 2004). Large scale studies are however missing in 
order to define more precisely the anxiolytic activity of the compound.  
Therefore, the present study was designed to assess the effect of Passiflora (Sedanxio®) as a first 
intention treatment in patients consulting their GP for anxiety disorders. 
Material and methods  
STUDY DESIGN 
This is an open, multicentre, observational and not interventional study conducted in general 
practice in Belgium. A representative sample of GPs from all over the country was solicited to 
enrol 1-20 consecutive patients attending the practice for anxiety disorders and to whom a first 
intention treatment of 2 times daily 2 capsules containing 200 mg of dry extract of Passiflora 
incarnata L. (hydro alcoholic extract (60% V/V) (2:1) of the aerial parts of Passiflora incarnata 
L. Passionflower) was prescribed (visit 1). Patients were then seen 2-8 weeks later (visit 2) to 
assess treatment outcome and continuation. 
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Age (years), gender, height (cm), weight (kg), smoking (> 10 cigarettes/day), alcohol (> 4 
glasses/day) and number of concomitant drugs were recorded at visit 1 (baseline). BMI (kg/m²) 
was computed from weight and height. At visit 2, the duration of treatment, its continuation 
(no/yes), and the number of concomitant drugs were noted.  
Assessment of anxiety was based on the Hamilton Anxiety Rating Scale (Hamilton, 1959) (HAM-
A) which was filled out by the patients at both visits. The HAM-A consists of 14 items scored on a 
5-point Likert scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe) with 
a total score range of 0 – 56. It is generally agreed that a score <17 indicates mild severity, 18-24 
mild to moderate severity, 25-30 moderate to severe, > 30 severe to very severe anxiety. 
Confirmed anxiety is often defined as HAM-A ≥ 20. The 14 items are, respectively, anxious mood, 
tension, fears, insomnia, intellectual, depressed mood, somatic (muscular), somatic (sensory), 
cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary 
symptoms, autonomic symptoms, and behaviour at interview.  
Two subscores were calculated from the HAM-A: the psychic anxiety score (HAM-AP) equal to 
the sum of items 1-6 and 14, and the somatic anxiety score (HAM-AS) equal to the sum of items 
7-13. Both subscores range in the interval 0-28.  
OUTCOME MEASURES  
To assess the treatment efficacy, the primary outcome measure was defined as the proportion of 
patients in remission (HAM-A ≤ 7) at visit 2.  
Secondary outcome measures included absolute or relative (%) change in HAM-A, HAM-AP, and 
HAM-AS scores between the two visits. Improvements of individual HAM-A items were also 
considered, improvement for a given item being defined as a visit 2 score strictly less than visit 1 
score.  
STUDY POPULATION  
The study or intention-to-treat (ITT) population consisted of all patients enrolled by their GPs 
for anxiety problems and who attended both visits. A more restricted population was defined as 
all patients of the ITT population aged 18-75 years and with “confirmed” anxiety (HAM-A ≥ 20).  
STATISTICAL METHODS  
Results were expressed as mean ± standard deviation (SD) for quantitative variables and 
scores, while frequency tables were used for categorical findings. For skewed distributions, the 
median was given together with the interquartile range (IQR). Mean values were compared by 
the Student t-test. McNemar test of symmetry was used to compare HAM-A item scores at the 
two visits.  
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The association between remission (primary outcome measure) and covariates was assessed by 
logistic regression. Odds ratios (OR) with 95% confidence intervals were calculated to measure 
the association between outcome and individual covariates. Multiple regression analysis was 
applied to analyse the relationship between a quantitative variable (e.g., change in HAM-A score 
– secondary outcome measures) and a set of covariates. The quality of the regression was 
appraised by the multiple coefficient of determination (R2).  
Before any calculations, outliers were detected and discarded from the analysis. A result was 
considered as an outlier if outside the interval Q1 – 1.5 H and Q3 + 1.5 H, where Q1 and Q3 are 
respectively the 25th and 75th percentiles (quartiles) of the sample distribution and H = Q3 – 
Q1, the H-spread.  
Results were considered significant at the 5% critical level (p<0.05). Calculations were 
performed with the SAS (version 9.2 for Windows) and S-PLUS (version 7.1) statistical pac-
kages.  
Results  
A total of 219 GPs participated in the study. They enrolled 2,928 patients consulting for anxiety 
problems and seen at both visits (recruitment rate: 13.4 ± 6.9 patients/GP).  
DEMOGRAPHIC CHARACTERISTICS  
The 2928 patients constituted the study population. Their characteristics are described in Table 
1. 
Table 1. Characteristics of the 2928 patients of the ITT population 
 
Variable Category Mean ± SD or No. (%) 
Age (years)  43.8 ± 17.2 
Gender Men 959 (33.2) 
 Women 1933 (66.8) 
Height (cm)  168.9 ± 8.51 
Weight (kg)  70.0 ± 13.3 
BMI (kg/m²)  24.5 ± 4.22 
Smoking > 10 cig/day 860 (31.6) 
Alcohol > 4 glasses/day 416 (15.5) 
Concomitant drugs* Number 2.1 ± 1.3 
 0 91 (7.0) 
 1 536 (41.3) 
 2 335 (25.8) 
 3 188 (14.5) 
 ≥ 4 148 (11.4) 
* Only available for 1298 patients 
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Patients were on average 43.8 ± 17.2 years old (range: 11 – 96) and there was a clear majority 
of women (66.8%). The mean BMI was 24.5 ± 4.22 kg/m² (range: 10.5 – 66.4 kg/m²). The 
proportion of smokers and drinkers were 31.6% and 15.5%, respectively. The number of 
concomitant drugs was only known for 1298 (44.3%). Almost all patients (93 %) took another 
medication and had on average 2.1 ± 1.3 concomitant drugs. 
BASELINE ANXIETY STATUS  
The distributions of the 14 items of the HAM-A scale and of the total score and subscores at 
baseline are summarized in Table 2. It is seen that the most affected items (i.e., proportion of 
subjects with a score ≥ 2) were insomnia (87.5%), anxious mood (84.7%) and tension (82.8%). 
The least affected items were autonomic symptoms (53.3%), somatic sensory (51.6%) and 
genitourinary symptoms (31.0%). The distribution of the total HAM-A score depicted in Figure 1 
appears to be fairly Gaussian with a mean value of 25.7 and a SD of 8.3, the median being 26.0. 
The proportion of patients with “confirmed” anxiety (HAM-A ≥ 20) was equal to 78.5%.  
Table 2. Distribution of the 14 items of the HAM-A at baseline (n = 2928 patients) 
Item Mean ± SD Proportion 
1. Anxious mood 2.4 ± 0.90 84.7 
2. Tension 2.3 ± 0.90 82.8 
3. Fears 1.7 ± 1.1 58.1 
4. Insomnia 2.5 ± 0.94 87.5 
5. Intellectual 1.9 ± 0.96 67.8 
6. Depressed mood 1.9 ± 1.0 64.9 
7. Somatic (muscular) 1.9 ± 1.0 65.4 
8. Somatic (sensory) 1.5 ± 1.0 51.6 
9. Cardiovascular symptoms 1.8 ± 0.98 63.9 
10. Respiratory symptoms 1.6 ± 1.0 55.2 
11. Gastrointestinal symptoms 1.8 ± 1.1 60.9 
12. Genitourinary symptoms 1.0 ± 1.0 31.0 
13. Autonomic symptoms 1.6 ± 1.0 53.3 
14. Behaviour at interview 1.9 ± 0.92 69.4 
HAM-A total score 25.7 ± 8.3 
(range: 
4 – 56) 
HAM-AP score 14.6 ± 4.4 
(range: 
0 – 28) 
HAM-AS score 11.1 ± 4.9 
(range: 
0 – 28) 
 
Finally, it is worth mentioning that the HAM-A psychic score was on average about 3.1 points 
higher than the corresponding somatic score (14.6 ± 4.4 for HAM-AP vs. 11.1 ± 4.9 for HAM-
AS), confirming the results of the items in Table 2.  
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TREATMENT CHARACTERISTICS  
The median time interval between the two patient visits was 22 days (IQR: 15 – 30 days) and the 
median treatment duration with Sedanxio® was 4 weeks (IQR: 2 – 4 weeks). The mean number 
of tablets taken per day was 3.4 ± 1.1 (range: 1 – 9), corresponding to a mean total dose of dry 
extract of Passiflora incarnata L. of 17,617 ± 11,494 mg (Median 16,800 mg; IQR 11,200 – 
22,400 mg). At visit 2, the treatment was pursued in 80.2% of the patients. 
Figure 1. Distribution of the HAM-A score at baseline in 2928 patients 
 
TREATMENT EFFICACY: PRIMARY OUTCOME MEASURE  
The proportion of patients in remission (HAM-A ≤ 7) at visit 2 was equal to 15.6% (95% CI: 14.2 
– 17.1%).  
By logistic regression, it was found that remission was not affected by gender (p=0.38), smoking 
(p=0.79) and treatment duration (p=0.47). By contrast, remitters were significantly younger 
than non-remitters (37.6 ± 16.4 vs. 44.9 ± 17.0 years, p<0.0001), their BMI was slightly lower 
(23.8 ± 4.0 vs. 24.5 ± 4.2 kg/m², p=0.0029), they were less often drinkers (9.0 vs. 16.4%, 
p=0.0006), they had less often concomitant drugs (82.7 vs. 94.2%, p<0.0001), their HAM-A 
score at baseline was lower (16.7 ± 6.8 vs. 27.3 ± 7.4, p<0.0001), and they took less Sedanxio® 
tablets per day (3.2 ± 1.2 vs. 3.4 ± 1.1, p<0.0001).  
When combining these factors into a multivariate logistic regression analysis, it turned out that 
only a low HAM-A score at baseline (OR = 1.26, 95% CI: 1.23 – 1.30) and a younger age (OR = 
1.02, 95% CI: 1.01 – 1.03) were positively associated with remission.  
TREATMENT EFFICACY: SECONDARY OUTCOME MEASURES  
The total HAM-A score at visit 2 was 15.4 ± 7.7 (see Figure 2), thus yielding a highly significant 
(p<0.0001) decrease of 10.2 ± 6.12 points from baseline. In terms of relative drop, the 
corresponding HAM-A change averaged 41 ± 22% (see Table 3). Multiple regression analysis 
showed that the HAM-A decrease was significantly higher for elevated HAM-A baseline score 
(p<0.0001) and when treatment duration was longer (p=0.030). By contrast, it was 
Published in : Acta Psychiatrica Belgica (2012), vol. 112, n° 2, pp. 5–11 




significantly lower for older patients (p=0.0010) and higher treatment doses (p=0.021). The 
quality of the regression however was low (R²=0.19).  
As seen in Table 3, the Hamilton psychic (HAM-AP) and somatic (HAM-AS) subscores also 
improved significantly from baseline after treatment. The HAM-AP score dropped by 5.7 ± 3.4 
points or by 40 ± 22% (p<0.0001), and the HAM-AS score decreased by 4.6 ± 3.5 points or 42 ± 
30% (p<0.0001). 
Table 3. Change in HAM-A score after treatment (n = 2928 patients) 
Variable N Visit 1 Visit 2 Change p-value 
HAM-A 2344 25.6 ± 8.3 15.4 ± 7.7 10.2 ± 6.1 <0.0001 
HAM-AP 2373 14.5 ± 4.3 8.9 ± 4.3 5.7 ± 3.4 <0.0001 
HAM-AS 2359 11.1 ± 4.9 6.5 ± 4.0 4.6 ± 3.5 <0.0001 
 
At visit 2, all individual items scores of the HAM-A dropped significantly from baseline 
(p<0.0001). Table 4 displays for each item the mean ± SD values at visit 2, the proportion of 
subjects who dropped by at least one point of the item scale, as well as the proportion of patients 
with an item score ≥ 2. It is seen that for almost all items (except genitourinary symptoms), a 
majority of patients had at least a 1-point decrease when compared to baseline. McNemar test 
confirmed that there was a highly significant downward shift for all items (p<0.0001). 








When comparing the proportions of patients with an item score ≥ 2 at visit 2 with those at 
baseline (see Table 2), there was again a clear improvement in the percentages. For example, 
insomnia which affected 87.5% of the patients at baseline did affect only 46.6% of the patients at 
visit 2. Overall, this item was also the most markedly improved (74.6% with at least 1-point 
change), followed by anxious mood (72.3%) and tension (69.1%).  
RESTRICTED POPULATION  
When restricting the ITT population to patients aged 18 – 75 years with a baseline HAM-A score 
≥ 20 (confirmed anxiety), a subsample of 1745 (59.6%) subjects was obtained. The demo-
graphic characteristics of these subjects were very similar to those of the general population: 
age (43.4 ± 14.9 years), gender (66.9% female), BMI (24.5 ± 4.3 kg/m²), smoking (33%), 
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alcohol (17.2%), and no. of concomitant drugs (1.9 ± 1.2). The total HAM-A score averaged 28.7 
± 6.4, obviously slightly higher, and so were the HAM-AP and HAM-AS subscores, respectively, 
15.9 ± 3.5 and 12.7 ± 4.0. The median time interval between the two visits was 22 days (IQR: 15 
- 29 days) and the median treatment duration was 4 weeks (IQR: 2 - 4 weeks). The mean 
number of medication tablets was 3.5 ± 1.1 (range: 1 - 9) corresponding to a total mean dose of 
17,976 ± 11,560 mg (median 16,8 mg; IQR 11,200 – 22,400 mg) as in the total study population. 
At visit 2, the treatment was continued in 82.6% of the patients. 
Table 4. Characteristics of HAM-A individual items at visit 2 
Item Score at visit 2 Proportion (%) with Proportion (%) 
1. Anxious mood 1.5 ± 0.79 72.3 45.8 
2. Tension 1.4 ± 0.80 69.1 43.6 
3. Fears 1.1 ± 0.86 51.8 29.3 
4. Insomnia 1.5 ± 0.88 74.6 46.6 
5. Intellectual 1.1 ± 0.84 59.6 30.5 
6. Depressed mood 1.2 ± 0.85 56.9 31.7 
7. Somatic (muscular) 1.1 ± 0.85 61.0 29.2 
8. Somatic (sensory) 0.9 ± 0.80 50.9 21.4 
9. Cardiovascular symptoms 1.0 ± 0.80 61.5 25.2 
10. Respiratory symptoms 0.9 ± 0.80 56.3 19.9 
11. Gastrointestinal symptoms 1.0 ± 0.85 58.9 26.1 
12. Genitourinary symptoms 0.6 ± 0.81 34.9 13.4 
13. Autonomic symptoms 0.9 ± 0.79 54.8 21.1 
14. Behaviour at interview 1.1 ± 0.79 66.4 27.3 
Significant drop from baseline for all items (p<0.0001) 
* 
 
As far as the primary outcome measure was concerned, a total of 7.1% patients were found to be 
in remission (HAM-A ≤ 7). This is less than half of the proportion (15.6%) found in the general 
population, indicating that the treatment efficacy was lower when considering patients with 
moderate to severe or very severe anxiety (HAM-A ≥ 20).  
For secondary outcome measures, as seen in Figure 3, a significant decrease was found between 
the two visits for the total HAM-A score (40 ± 20%; p<0.0001). An improvement also occurred 
for the psychic HAM-AP subscore (38 ± 20%; p<0.0001) and the somatic HAM-AS subscore (41 
± 26%; p<0.0001). These findings were quite comparable to those obtained for the total 
population (see Table 3). Likewise, all 14 items of the HAM-A scale improved significantly after 
treatment (p<0.0001), with special mention for insomnia, anxious mood, tension and behaviour 
at interview.  
Discussion  
The present study was designed to assess the efficacy of a first intention treatment with a dry 
extract of Passiflora incarnata L. (Sedanxio® capsules) in patients consulting their general prac-
titioners for anxiety disorders. The observational, non-interventional nature of the study 
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necessarily induced a number of biases and limitations (e.g., no control group, lenient inclusion 
and exclusion criteria, lack of control on some managerial and clinical factors, absence of 
randomization, presence of spurious results), which were partly tempered by the large size of 
the population of patients enrolled and the use of robust statistical techniques to avoid outlying 
and highly influential observations. It has been evidenced that conclusions drawn from the 
entire patient population were very similar to those obtained from the restricted subgroup of 18 
– 75 years old patients with confirmed anxiety (HAM-A ≥ 20). 
Figure 3. Improvement of the HAM-A total score from baseline after Sedanxio® treatment (n=1745 patients) 




The present study showed that two thirds of the patients consulting for anxiety disorders in 
general practice were women. Fifty percents of the patients were in the age range 30 – 56 years 
and with moderate to severe overweight (BMI ≥ 23.9 kg/m²). About one third was smokers and 
15% were alcohol drinkers. Data about concomitant drugs were captured for less than half of 
the patients but revealed that 93% of them did take other medications. The demographic 
characteristics of the study patients seem to correspond pretty well with those of the population 
attending a GP visit for depressive and/or anxious symptoms. The anxiety profile of the patients 
as assessed by the HAM-A scale varied widely from mild to very severe cases. We found that a 
substantial proportion of the subjects enrolled (approximately 60%) had “confirmed” anxiety 
(HAM-A ≥ 20).  
Despite the potential limitations of the study design, first intention treatment with a dry extract 
of Passiflora incarnata L. (capsules) demonstrated an overall remission rate of 15.6% for the 
general study population and of 7.1% for the subgroup of moderate to very severe anxiety 
patients. Likewise, total HAM-A score, HAM-AP and HAM-AS subscores, as well as all 14 
individual items of the HAM-A significantly improved at visit 2 (treatment outcome) as 
compared to baseline. Insomnia, anxious mood and tension items were particularly reduced by 
the treatment.  
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The beneficial efficacy of Sedanxio® treatment of anxiety evidenced in this study has to be 
interpreted with caution since no control was made of other anxiolytics and antidepressant 
drugs taken by the patient (such as BZDs). Moreover, although the selection of patients was such 
that Sedanxio® was prescribed as first intention treatment, there is no guarantee that patients 
previously or currently treated with other drugs were not massively included in the study.  
When analysing factors likely to affect the remission rate, it was found that patients with 
elevated HAM-A score at initiation of the treatment (baseline), i.e., highly anxious subjects, were 
less likely to remit than the others. This finding seems logical as it is not really expected that 
Sedanxio® treatment, even during a prolonged period of time, will cure patients with a long 
history and/or severity of anxiety. However, it was also observed that older patients did perform 
worse than younger ones in terms of remission. This observation deserves some attention since 
not all elderly patients exhibit a long history of anxiety disease. 
Assessment of anxiety in older patients with the HAM-A scale may not be appropriate or 
sufficiently refined to assess severity.  
When considering covariates potentially influencing the drop in HAM-A score and subscores 
after Sedanxio® treatment, it was found that the higher the HAM-A score at baseline, the more 
important the drop after treatment. The latter however was often not sufficient to reach 
remission. This observation is made in many studies on anxiety and depression. For patients 
with high baseline scores, the range of the potential decrease is wider than for patients with low 
baseline scores, because of the numerical score of the scale itself. Finally, age was confirmed to 
be negatively correlated with improvement of anxiety scores. Indeed, older subjects had more 
difficulties to bring their anxiety severity level down than younger patients.  
In the present study, compliance to the treatment was not recorded. It is therefore difficult to 
assess its impact on the study results. Due to the large number of patients enrolled, the as-
sumption can be made that a majority of them took the capsules regularly and respected the 
prescribed doses. Although dose related information was also subject to caution, no significant 
relationship was evidenced between dose prescribed and treatment effect on anxiety remission 
and severity. This may support the assumption that GPs administered the appropriate dose re-
gimen to the patient’s individual anxiety status.  
The results of the present study support anxiolytic activity of Sedanxio®. They confirm several 
reports. In particular, a placebo-controlled study showed that in outpatient surgery, the 
administration of Sedanxio® as a premedication reduces anxiety without inducing sedation 
(Movafegh et al., 2008). Similarly, oral preoperative intake of Sedanxio® suppresses the increase 
in anxiety before spinal anaesthesia without changing psychomotor function test results, 
sedation level, or hemodynamics (Aslanargun et al., 2011). A recent systematic review of 
nutritional and herbal supplements for anxiety and anxiety-related disorders showed 
improvement in symptomatology without the risk of serious site-effects (Lakhan & Vieira, 
2010).  
Sedanxio® could represent an interesting alternative for benzodiazepines. Indeed, Sedanxio® 
appears devoid of site-effects typical of benzodiazepines, in particular, sedation and memory 
disturbances (Ansseau and Sabbe, 2003).  
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In addition, the major limitation of benzodiazepines comes from their potential for abuse and 
dependence. In particular, they can be responsible for a withdrawal syndrome which can be of 
high severity with panic attacks, seizures, confusion, hyperesthesia. Sedanxio® appears devoid of 
such abuse and/or dependence potential.  
In conclusion, the present Belgian open, observational, non-interventional study on patients 
consulting for anxiety problems in general practice has demonstrated a remission rate (HAM-A 
≤ 7) of 7 – 15% and a highly significant reduction in HAM-A scores and subscores, as well as in 
individual item scores, after 2 – 4 weeks of first intention treatment with a dry extract of 
Passiflora incarnata L. (capsules). The total HAM-A score decreased by 41 % between the two 
visits. The most markedly items improved were insomnia followed by anxious mood and 
tension. At visit 2, the treatment was continued in 80.6% of the patients.  
Despite the limitations of observational studies, the salient findings of this study add therapeutic 
evidence on the beneficial effects of Sedanxio® in the care management of anxiety in general 
practice. 
Résumé 
L’objectif de cette étude était d’évaluer l’efficacité d’un extrait sec de Passiflora incarnata L 
(Sedanxio®) chez des patients consultant leur médecin traitant pour de l’anxiété. Un total de 
2928 patients ont été recrutés par 219 médecins généralistes. Les patients étaient évalués au 
début du traitement et 2 semaines plus tard avec l’échelle d’anxiété de Hamilton. Les résultats 
mettent en évidence une amélioration très significative dans les scores d’anxiété, de 25.6 (SD = 
8.3) à la visite 1 à 15.4 (SD = 7.7) à la visite 2 (-41%) (p < 0.0001). Les sous-scores d’anxiété 
psychique et somatique de l’échelle de Hamilton se sont également améliorés. De plus, 15.6 % 
des patients pouvaient être considérés comme en rémission à la visite 2 (Echelle d’anxiété de 
Hamilton inférieure à 7). Ces résultats démontrent l’intérêt de la passiflore comme traitement de 
première ligne des symptômes anxieux. 
Samenvatting 
Het doel van deze studie bestond erin om de werkzaamheid van een droog extract van Passiflora 
incarnata L (Sedanxio®) te evalueren bij patiënten die een huisarts consulteren voor angst. In 
totaal werden 2928 patiënten gerekruteerd door 219 huisartsen. De patiënten werden in het 
begin van de behandeling en twee weken later geëvalueerd met de Hamilton angst schaal. De 
resultaten tonen een zeer significante verbetering van de angst score, van 25.6 (SD=8.3) bij het 
eerste bezoek naar 15.4 (SD= 7.7) bij het tweede bezoek (-41%) (p<0.0001). Zowel de score 
van de psychische angst als deze van de somatische angst zijn verbeterd. Daarenboven zijn al 
15.6 % van de patiënten in remissie bij het tweede bezoek (Hamilton angstscore onder de 7 ). 
Deze resultaten tonen het belang van passiflora in de eerste lijnsbehandeling van de angst 
symptomen. 
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